What is a glioblastoma?

por Lassman, Andrew B, van den Bent, Martin J
Publicado 2023

COVD-20. COVID-19 INFECTION DURING CHEMOTHERAPY FOR MALIGNANT GLIOMA: OUTCOMES AMONG 3 PATIENTS

por Kim, Esther, Koshy, Amily, Higgins, Shannon, Lassman, Andrew, Iwamoto, Fabio
Publicado 2020

Current usage of tumor treating fields for glioblastoma

por Lassman, Andrew B, Joanta-Gomez, Adela E, Pan, Peter C, Wick, Wolfgang
Publicado 2020

LPTO-02. INTRATHECAL (IT) TRASTUZUMAB (T) FOR THE TREATMENT OF LEPTOMENINGEAL DISEASE (LM) IN PATIENTS (PTS) WITH HUMAN EPIDERMAL RECEPTOR-2 POSITIVE (HER2+) CANCER: A MULTICENTER...

por Kumthekar, Priya, Lassman, Andrew B, Lin, Nancy, Grimm, Sean, Gradishar, William, Pentsova, Elena, Jeyapalan, Suriya, Groves, Morris, Melisko, Melissa, Raizer, Jeffrey
Publicado 2019

Causes of Death and End-of-Life Care in Patients With Intracranial High-Grade Gliomas: A Retrospective Observational Study

por Barbaro, Marissa, Blinderman, Craig D., Iwamoto, Fabio M., Kreisl, Teri N., Welch, Mary R., Odia, Yazmin, Donovan, Laura E., Joanta-Gomez, Adela E., Evans, Katharine A., Lassman, Andrew B.
Publicado 2022

TIPS-08 ACTION: A RANDOMIZED PHASE 3 STUDY OF DORDAVIPRONE (ONC201) IN PATIENTS WITH NEWLY DIAGNOSED H3 K27M-MUTANT DIFFUSE GLIOMA

por Arrillaga-Romany, Isabel, Lassman, Andrew, McGovern, Susan, Mueller, Sabine, Nabors, Louis Burt, van den Bent, Martin, Vogelbaum, Michael, Allen, Joshua E, Melemed, Allen S, Tarapore, Rohinton, Wen, Patrick, Cloughsey, Timothy
Publicado 2023

A Phase 3b Study for Management of Ocular Side Effects in Patients with Epidermal Growth Factor Receptor-Amplified Glioblastoma Receiving Depatuxizumab Mafodotin

por Vize, Colin J., Kim, Stella K., Matthews, Tim, Macsai, Marian, Merrell, Ryan, Hsu, Sigmund, Kundu, Madan Gopal, Yoon, Jennifer, Kennedy, Emma, Pai, Madhavi, Bain, Earle, Lassman, Andrew B., Moazami, Golnaz
Publicado 2023

Urgent considerations for the neuro-oncologic treatment of patients with gliomas during the COVID-19 pandemic

por Mohile, Nimish A, Blakeley, Jaishri O, Gatson, Na Tosha N, Hottinger, Andreas F, Lassman, Andrew B, Ney, Douglas E, Olar, Adriana, Schiff, David, Shih, Helen A, Strowd, Roy, van den Bent, Martin J, Ziu, Mateo
Publicado 2020

Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma

por Kaley, Thomas J., Panageas, Katherine S., Pentsova, Elena I., Mellinghoff, Ingo K., Nolan, Craig, Gavrilovic, Igor, DeAngelis, Lisa M., Abrey, Lauren E., Holland, Eric C., Omuro, Antonio, Lacouture, Mario E., Ludwig, Emmy, Lassman, Andrew B.
Publicado 2020

Tumor volumes as a predictor of response to the anti-EGFR antibody drug conjugate depatuxizumab mafadotin

por Gan, Hui K, Parakh, Sagun, Lassman, Andrew B, Seow, Aidan, Lau, Eddie, Lee, Sze Ting, Ameratunga, Malaka, Perchyonok, Yuliya, Cao, Diana, Burvenich, Ingrid J G, O’Keefe, Graeme J, Rigopoulos, Angela, Gomez, Erica, Maag, David, Scott, Andrew M
Publicado 2021

Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancer

por Malani, Rachna, Fleisher, Martin, Kumthekar, Priya, Lin, Xuling, Omuro, Antonio, Groves, Morris D., Lin, Nancy U., Melisko, Michelle, Lassman, Andrew B., Jeyapalan, Suriya, Seidman, Andrew, Skakodub, Anna, Boire, Adrienne, DeAngelis, Lisa M., Rosenblum, Marc, Raizer, Jeffrey, Pentsova, Elena
Publicado 2020

Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival

por Ellingson, Benjamin M, Wen, Patrick Y, Chang, Susan M, van den Bent, Martin, Vogelbaum, Michael A, Li, Gang, Li, Shanpeng, Kim, Jiyoon, Youssef, Gilbert, Wick, Wolfgang, Lassman, Andrew B, Gilbert, Mark R, de Groot, John F, Weller, Michael, Galanis, Evanthia, Cloughesy, Timothy F
Publicado 2023

A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma

por van den Bent, Martin, Azaro, Analia, De Vos, Filip, Sepulveda, Juan, Yung, W. K. Alfred, Wen, Patrick Y., Lassman, Andrew B., Joerger, Markus, Tabatabai, Ghazaleh, Rodon, Jordi, Tiedt, Ralph, Zhao, Sylvia, Kirsilae, Tiina, Cheng, Yi, Vicente, Sergio, Balbin, O. Alejandro, Zhang, Hefei, Wick, Wolfgang
Publicado 2019

A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma

por Lassman, Andrew B., Wen, Patrick Y., van den Bent, Martin J., Plotkin, Scott R., Walenkamp, Annemiek M.E., Green, Adam L., Li, Kai, Walker, Christopher J., Chang, Hua, Tamir, Sharon, Henegar, Leah, Shen, Yao, Alvarez, Mariano J., Califano, Andrea, Landesman, Yosef, Kauffman, Michael G., Shacham, Sharon, Mau-Sørensen, Morten
Publicado 2022

Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A Bayesian Adaptive Platform Trial to Develop Precision Medicines for Patients With Glioblastoma

por Alexander, Brian M., Trippa, Lorenzo, Gaffey, Sarah, Arrillaga-Romany, Isabel C., Lee, Eudocia Q., Rinne, Mikael L., Ahluwalia, Manmeet S., Colman, Howard, Fell, Geoffrey, Galanis, Evanthia, de Groot, John, Drappatz, Jan, Lassman, Andrew B., Meredith, David M., Nabors, L. Burt, Santagata, Sandro, Schiff, David, Welch, Mary R., Ligon, Keith L., Wen, Patrick Y.
Publicado 2019

CLRM-07 RANO 2.0: PROPOSAL FOR AN UPDATE TO THE RESPONSE ASSESSMENT IN NEURO-ONCOLOGY (RANO) CRITERIA FOR HIGH- AND LOW-GRADE GLIOMAS IN ADULTS

por Wen, Patrick, Van Den Bent, Martin, Youssef, Gilbert, Cloughesy, Timothy, Ellingson, Benjamin, Weller, Michael, Galanis, Evanthia, Barboriak, Danial, DeGroot, John, Gilbert, Mark, Huang, Raymond, Lassman, Andrew, Mehta, Minesh, Molinaro, Annette, Preusser, Mattias, Rahman, Rifaquat, Shankar, Lalitha, Stupp, Roger, Sul, Joohee, Villanueva-Meyer, Javier, Wick, Wolfgang, Macdonald, David, Reardon, David, Vogelbaum, Michael, Chang, Susan
Publicado 2023

Report of National Brain Tumor Society roundtable workshop on innovating brain tumor clinical trials: building on lessons learned from COVID-19 experience

por Lee, Eudocia Q, Selig, Wendy, Meehan, Clair, Bacha, Jeffrey, Barone, Amy, Bloomquist, Erik, Chang, Susan M, de Groot, John F, Galanis, Evanthia, Hassan, Islam, Kalidas, Chitkala, Khasraw, Mustafa, Kvedar, Joseph C, Lassman, Andrew B, Puduvalli, Vinay, Sahebjam, Solmaz, Schwamm, Lee H, Tamir, Sharon, Welch, Mary, Yung, W K Alfred, Zadeh, Gelareh, Arons, David, Wen, Patrick Y
Publicado 2021

Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study

por Lassman, Andrew B., Sepúlveda-Sánchez, Juan Manuel, Cloughesy, Timothy F., Gil-Gil, Miguel J., Puduvalli, Vinay K., Raizer, Jeffrey J., De Vos, Filip Y.F., Wen, Patrick Y., Butowski, Nicholas A., Clement, Paul M.J., Groves, Morris D., Belda-Iniesta, Cristóbal, Giglio, Pierre, Soifer, Harris S., Rowsey, Steven, Xu, Cindy, Avogadri, Francesca, Wei, Ge, Moran, Susan, Roth, Patrick
Publicado 2022

Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study

por van den Bent, Martin, Gan, Hui K., Lassman, Andrew B., Kumthekar, Priya, Merrell, Ryan, Butowski, Nicholas, Lwin, Zarnie, Mikkelsen, Tom, Nabors, Louis B., Papadopoulos, Kyriakos P., Penas-Prado, Marta, Simes, John, Wheeler, Helen, Walbert, Tobias, Scott, Andrew M., Gomez, Erica, Lee, Ho-Jin, Roberts-Rapp, Lisa, Xiong, Hao, Bain, Earle, Ansell, Peter J., Holen, Kyle D., Maag, David, Reardon, David A.
Publicado 2017

Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial

por Lassman, Andrew B, van den Bent, Martin J, Gan, Hui K, Reardon, David A, Kumthekar, Priya, Butowski, Nicholas, Lwin, Zarnie, Mikkelsen, Tom, Nabors, Louis B, Papadopoulos, Kyriakos P, Penas-Prado, Marta, Simes, John, Wheeler, Helen, Walbert, Tobias, Scott, Andrew M, Gomez, Erica, Lee, Ho-Jin, Roberts-Rapp, Lisa, Xiong, Hao, Ansell, Peter J, Bain, Earle, Holen, Kyle D, Maag, David, Merrell, Ryan
Publicado 2019